Dec 15, 2025
Sanofi (SNY) Stock: Falls After MS Drug Suffers Double Blow
Tolebrutinib failed phase 3 trial for primary progressive MS and faces FDA delay. Sanofi drops regulatory plans but continues work on other MS forms.
The post Sanofi (SNY) Stock: Falls After MS Drug Suffers Double Blow appeared first on Blockonomi.
Source: Blockonomi →Related News
- 6 hours ago
Uniswap Price Compression Signals Potential Breakout Toward $5.30
- 6 hours ago
Tron Revenue Tops Blockchain Networks with $24.96M Monthly Earnings
- 7 hours ago
HYPE Token Shows Net Daily Emission as HyperCore Buybacks Fall Short of Rewards
- 7 hours ago
Is Bittensor (TAO) the Next Big Crypto Move? Investors Point to Revenue, Scarcit...
- 8 hours ago
Injective Flips Bearish Structure After Monthly Order Block Holds: What’s Next f...